Who is this trial for?
This trial was for adults with advanced biliary tract cancer — cancer of the bile ducts or gallbladder — that could not be removed by surgery and had not yet been treated.
People in the trial had:
- Biliary tract cancer that was locally advanced (too extensive to remove) or metastatic (spread to other organs).
- No previous treatment for their advanced cancer.
- Good enough general health to receive chemotherapy.
What kind of trial is this?
This trial tested whether adding immunotherapy to standard chemotherapy could do better at treating advanced biliary tract cancer.
Background: why researchers asked this question
Since a landmark trial more than a decade ago, the standard first treatment for advanced biliary tract cancer has been the chemotherapy pair gemcitabine and cisplatin. It helps, but not for long — and there had been no successful improvement on it for years. This is a cancer in urgent need of better options.
Immunotherapy had transformed the treatment of several other cancers. Researchers asked whether adding durvalumab — an immunotherapy that blocks the PD-L1 “off-switch” tumors use to hide from the immune system — to the standard chemotherapy could help people live longer.
The trial: what was tested and how
TOPAZ-1 enrolled 685 people with advanced biliary tract cancer across 17 countries. They were randomly assigned to one of two groups:
- Durvalumab group (341 people): durvalumab plus gemcitabine–cisplatin chemotherapy, then durvalumab alone continued afterward.
- Placebo group (344 people): a dummy infusion plus the same gemcitabine–cisplatin chemotherapy.
Neither patients nor doctors knew which group they were in. The main measure was overall survival — how long people lived. Because quality of life matters so much in a serious illness, the trial also carefully tracked patients’ own reports of how they were feeling.
Results: what they found
Adding durvalumab helped people live longer — and, importantly, did so without making their quality of life worse.
Durvalumab + chemo vs chemo alone
A modest gain in the average, but a meaningful 20–24% lower risk of dying overall (HR 0.80 at first analysis, 0.76 with longer follow-up).
More than twice as many people were alive at 2 years — the durable benefit that matters most, as a subset of patients did far better than average.
Patients’ own reports of how they felt — overall health, daily functioning, and symptoms — were not made worse by adding durvalumab.
Side effects were largely those of the chemotherapy: serious (grade 3 or 4) side effects occurred in roughly three-quarters of people in both groups, so adding durvalumab did not meaningfully increase them. As with any immunotherapy, the immune system can occasionally attack healthy tissue, which requires monitoring.
Why focus on 2-year survival instead of the average?
When only the average (median) survival is reported, immunotherapy can look unimpressive — here the average improved by barely more than a month. But averages hide the most important effect: a group of people who respond to immunotherapy and live much longer than expected. Looking at how many are alive at 2 years captures that “tail” — and there, the difference is striking (roughly 1 in 4 versus 1 in 10).
The bottom line
For advanced biliary tract (bile duct and gallbladder) cancer, adding durvalumab immunotherapy to standard gemcitabine–cisplatin chemotherapy improved survival — more than doubling the share of people alive at two years — without worsening quality of life or adding much toxicity. It was the first advance on a treatment that had gone unchanged for more than a decade, and durvalumab plus chemotherapy is now a standard first option.
What this could mean for you
- The average gain is small, but the tail matters. The biggest benefit is for the subset of people who respond and go on to longer survival.
- Quality of life was preserved. The extra treatment did not make people feel worse — an important point in a serious illness.
- Biomarker testing is worth discussing. Biliary tract cancers can also carry targetable mutations; ask your oncologist about molecular testing alongside this approach.
Related summary: HIMALAYA — the same immunotherapy, durvalumab, used in liver cancer.
Questions & comments
Have a question about this trial? Ask below. Questions are read and answered by the site. We can’t give personal medical advice, but we’re glad to explain the research more clearly.